-
11.发明公开公开(公告)号：US20230218735A1
公开(公告)日：2023-07-13
申请号：US18001953
申请日：2021-06-17
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , William Carl Gruber , Kathrin Ute Jansen , Lakshmi Khandke , Nicholas Randolph Everard Kitchin , Jody Lawrence , Yahong Peng , Michael William Pride , Christopher Frederick Webber , Sabine Susanne Wellnitz , Zhuobiao Yi
CPC classification number: A61K39/08 , A61K47/26 , A61K9/19 , C07K16/1282 , A61P31/04 , A61K2039/55577
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US20220160859A1
公开(公告)日：2022-05-26
申请号：US17594107
申请日：2020-03-30
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , Nicholas Randolph Everard Kitchin , Paul Liberator , Michael William Pride , Christopher Frederick Webber
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US10786561B2
公开(公告)日：2020-09-29
申请号：US15775485
申请日：2016-11-07
Applicant: Pfizer Inc.
Inventor： Fiona Laichu Lin , Viliam Pavliak , Michael William Pride , Shite Sebastian
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
14.发明申请公开(公告)号：US20180099039A1
公开(公告)日：2018-04-12
申请号：US15286696
申请日：2016-10-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
15.发明授权公开(公告)号：US11872274B2
公开(公告)日：2024-01-16
申请号：US17194224
申请日：2021-03-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-Ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/30
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
Patent Agency Ranking
公开(公告)号：US20230190907A1
公开(公告)日：2023-06-22
申请号：US17812777
申请日：2022-07-15
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/55505
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
公开(公告)号：US11413344B2
公开(公告)日：2022-08-16
申请号：US16478265
申请日：2018-01-05
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
公开(公告)号：US11135279B2
公开(公告)日：2021-10-05
申请号：US16844060
申请日：2020-04-09
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
IPC: A61K39/00 , A61K39/02 , A61K39/09 , A61K39/385
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
-
19.发明申请公开(公告)号：US20210196810A1
公开(公告)日：2021-07-01
申请号：US17194224
申请日：2021-03-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
20.发明申请公开(公告)号：US20200306357A1
公开(公告)日：2020-10-01
申请号：US16899738
申请日：2020-06-12
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.022 seconds)
